Q-omics provides the consensus-scored FTLP15 profile across patient tissues and cancer cell-line models. FTLP15 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FTLP15 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FTLP15 RNA expression shows 13,123 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where FTLP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTLP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTLP15 survival associations across molecular data types. FTLP15 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTLP15 RNA expression–survival associations across cancer types. High FTLP15 expression shows unfavorable associations in UVM, STAD, UCEC, OV and MESO, but favorable associations in SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for FTLP15 RNA expression.
This table summarizes FTLP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FTLP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTLP15 shows lower tumor expression in BRCA, UCEC and KICH and higher tumor expression in KIRC, LIHC and STAD. The KIRC box plot shows higher FTLP15 RNA expression in tumor versus normal tissue (log2 FC = +0.682, t-test p < 0.001).
This table shows molecular features associated with FTLP15 in patient tissues and cancer cell lines. In patient samples, FTLP15 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
